Literature DB >> 14508856

Prognostic factors in non-small cell lung cancer.

Merrill J Solan1, Maria Werner-Wasik.   

Abstract

Identification of prognostic factors is critical in optimizing treatment for patients with cancer. The purpose of this work is to review the modern literature with regard to prognostic factors for patients with non-small-cell lung cancer (NSCLC) taking into account ongoing advances in clinical evaluation, staging, surgery, radiation therapy, chemotherapy, and molecular biology in this widely heterogeneous patient population. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2003        PMID: 14508856     DOI: 10.1002/ssu.10023

Source DB:  PubMed          Journal:  Semin Surg Oncol        ISSN: 1098-2388


  11 in total

1.  Previous tumour as a prognostic factor in stage I non-small cell lung cancer.

Authors:  Angel López-Encuentra; Agustín Gómez de la Cámara; Ramón Rami-Porta; José Luis Duque-Medina; José Luis Martín de Nicolás; Javier Sayas
Journal:  Thorax       Date:  2006-01-31       Impact factor: 9.139

2.  Prognostic factors for patients with advanced non-small cell lung cancer treated with gemcitabine-platinum as first-line therapy in an observational setting in China.

Authors:  Wenyu Ye; Yicheng Yang; Jin Wang; Zbigniew Kadziola; Narayan Rajan; Shukui Qin
Journal:  Thorac Cancer       Date:  2014-07-03       Impact factor: 3.500

3.  Combining clinical, pathological, and demographic factors refines prognosis of lung cancer: a population-based study.

Authors:  Joseph Putila; Scot C Remick; Nancy Lan Guo
Journal:  PLoS One       Date:  2011-02-25       Impact factor: 3.240

4.  A Validated Prediction Model for Overall Survival From Stage III Non-Small Cell Lung Cancer: Toward Survival Prediction for Individual Patients.

Authors:  Cary Oberije; Dirk De Ruysscher; Ruud Houben; Michel van de Heuvel; Wilma Uyterlinde; Joseph O Deasy; Jose Belderbos; Anne-Marie C Dingemans; Andreas Rimner; Shaun Din; Philippe Lambin
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-04-30       Impact factor: 7.038

5.  Developing and Validating a Survival Prediction Model for NSCLC Patients Through Distributed Learning Across 3 Countries.

Authors:  Arthur Jochems; Timo M Deist; Issam El Naqa; Marc Kessler; Chuck Mayo; Jackson Reeves; Shruti Jolly; Martha Matuszak; Randall Ten Haken; Johan van Soest; Cary Oberije; Corinne Faivre-Finn; Gareth Price; Dirk de Ruysscher; Philippe Lambin; Andre Dekker
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-04-24       Impact factor: 7.038

6.  Are comorbidities associated with long-term survival of lung cancer? A population-based cohort study from French cancer registries.

Authors:  A Seigneurin; P Delafosse; B Trétarre; A S Woronoff; M Velten; P Grosclaude; A V Guizard; B Lapôtre-Ledoux; S Bara; F Molinié; M Colonna
Journal:  BMC Cancer       Date:  2018-11-12       Impact factor: 4.430

7.  Socioeconomic Differences and Lung Cancer Survival-Systematic Review and Meta-Analysis.

Authors:  Isabelle Finke; Gundula Behrens; Linda Weisser; Hermann Brenner; Lina Jansen
Journal:  Front Oncol       Date:  2018-11-27       Impact factor: 6.244

8.  Interleukin-17 promotes angiogenesis by stimulating VEGF production of cancer cells via the STAT3/GIV signaling pathway in non-small-cell lung cancer.

Authors:  Bo Pan; Jing Shen; Jingyan Cao; Yongxu Zhou; Lihua Shang; Shi Jin; Shoubo Cao; Dehai Che; Fang Liu; Yan Yu
Journal:  Sci Rep       Date:  2015-11-03       Impact factor: 4.379

9.  Association between EGFR/KRAS mutation and expression of VEGFA, VEGFR and VEGFR2 in lung adenocarcinoma.

Authors:  Xiao-Han Yuan; Jie Yang; Xin-Yue Wang; Xiao-Ling Zhang; Ting-Ting Qin; Kai Li
Journal:  Oncol Lett       Date:  2018-06-05       Impact factor: 2.967

10.  The prognostic value of the ratio of neutrophils to lymphocytes before and after intensity modulated radiotherapy for patients with nasopharyngeal carcinoma.

Authors:  Jing Liu; Changwu Wei; Haijun Tang; Yun Liu; Wenqi Liu; Chengsen Lin
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.